- Home
- XGN vs NTHI Comparison
XGN vs NTHI Comparison
Compare XGN & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XGN | NTHI |
|---|---|---|
| Founded | 2002 | 2008 |
| Country | United States | United States |
| Employees | N/A | 5 |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.7M | 114.6M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | XGN | NTHI |
|---|---|---|
| Price | $4.48 | $4.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | $8.86 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 208.3K | 94.9K |
| Earning Date | 05-11-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.12 | N/A |
| Revenue Next Year | $13.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.59 | $3.71 |
| 52 Week High | $12.23 | $12.99 |
Technical Indicators
Market Signals| Indicator | XGN | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 49.73 | 45.30 |
| Support Level | $4.11 | $4.49 |
| Resistance Level | $4.93 | $5.78 |
| Average True Range (ATR) | 0.32 | 0.28 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 26.92 | 26.46 |
Price Performance
Historical ComparisonAbout XGN Exagen Inc.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.
About NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.